Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...
The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...
Waters has announced the completion of its acquisition of BD’s Biosciences and Diagnostic Solutions businesses.
Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.
A new study may change the way scientists think about the distance traveled by tiny bubbles carrying signals between cells that are embedded in tissue. These particles, called extracellular vesicles, ...
The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
Biotium launched GlycoLinerTM cell surface labeling kits using self-catalyzing aminooxy chemistry to tag glycoproteins at ...
FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.
Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...
Waters Corporation (NYSE:WAT) Q4 2025 Earnings Call Transcript February 9, 2026 Waters Corporation beats earnings ...
Multiple sclerosis B-cell profiles differ by ancestry and sex among Black and Hispanic patients with multiple sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results